Trial intelligence / Profile preview

GMMG HD8/DSMM XIX IV vs SC isatuximab with RVd in transplant-eligible newly diagnosed multiple myeloma

2024-516300-41-00Phase 3Completed

Sponsor: Heidelberg University Hospital
Start: Nov 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 2

Overview

Phase 3, randomised trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Very good partial response or better rate after induction. Started Nov 2024; status: completed.

Drugs

isatuximab

Conditions

multiple myeloma (MM)

Beyond the preview

Go deeper on 2024-516300-41-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-516300-41-00.